Genfit S.A. (GNFT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.574x

Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.574x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-30.10 Million ≈ $-35.19 Million USD) by net assets (€52.47 Million ≈ $61.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Genfit S.A. - Cash Flow Conversion Efficiency Trend (2003–2024)

This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Genfit S.A. balance sheet liabilities for a breakdown of total debt and financial obligations.

Genfit S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Plastika Kritis S.A.
AT:PLAKR
0.019x
MCI Management SA
WAR:MCI
0.023x
North American Construction Group Ltd
TO:NOA
0.117x
North American Financial 15
TO:FFN
0.060x
GREENLIGHT CAP.RE A DL-01
F:G8L
N/A
Wonderful Hi-Tech Co Ltd
TWO:6190
0.067x
Shinsung Tngsn
KO:005390
0.167x
Tera Light Ltd
TA:TRLT
0.031x

Annual Cash Flow Conversion Efficiency for Genfit S.A. (2003–2024)

The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Genfit S.A. worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €69.22 Million
≈ $80.93 Million
€15.55 Million
≈ $18.18 Million
0.225x +127.54%
2023-12-31 €67.95 Million
≈ $79.44 Million
€-55.43 Million
≈ $-64.80 Million
-0.816x -6.15%
2022-12-31 €94.53 Million
≈ $110.51 Million
€-72.64 Million
≈ $-84.92 Million
-0.768x -191.60%
2021-12-31 €119.10 Million
≈ $139.24 Million
€99.92 Million
≈ $116.81 Million
0.839x -85.93%
2020-12-31 €-16.16 Million
≈ $-18.90 Million
€-96.37 Million
≈ $-112.67 Million
5.963x +1151.31%
2019-12-31 €84.06 Million
≈ $98.28 Million
€-47.68 Million
≈ $-55.74 Million
-0.567x +78.82%
2018-12-31 €20.94 Million
≈ $24.48 Million
€-56.08 Million
≈ $-65.56 Million
-2.678x -459.93%
2017-12-31 €104.23 Million
≈ $121.85 Million
€-49.86 Million
≈ $-58.29 Million
-0.478x -150.88%
2016-12-31 €142.80 Million
≈ $166.94 Million
€-27.23 Million
≈ $-31.83 Million
-0.191x +28.95%
2015-12-31 €55.42 Million
≈ $64.79 Million
€-14.87 Million
≈ $-17.38 Million
-0.268x -21.99%
2014-12-31 €70.43 Million
≈ $82.34 Million
€-15.49 Million
≈ $-18.11 Million
-0.220x +66.27%
2013-12-31 €14.09 Million
≈ $16.48 Million
€-9.19 Million
≈ $-10.75 Million
-0.652x +43.31%
2012-12-31 €6.83 Million
≈ $7.99 Million
€-7.86 Million
≈ $-9.19 Million
-1.150x +27.92%
2011-12-31 €4.46 Million
≈ $5.21 Million
€-7.11 Million
≈ $-8.32 Million
-1.596x -148.23%
2010-12-31 €8.39 Million
≈ $9.81 Million
€-5.39 Million
≈ $-6.31 Million
-0.643x -4415.44%
2009-12-31 €15.52 Million
≈ $18.14 Million
€-221.00K
≈ $-258.37K
-0.014x +93.83%
2008-12-31 €22.38 Million
≈ $26.17 Million
€-5.16 Million
≈ $-6.04 Million
-0.231x -21.55%
2007-12-31 €25.37 Million
≈ $29.66 Million
€-4.81 Million
≈ $-5.63 Million
-0.190x -202.28%
2006-12-31 €27.77 Million
≈ $32.47 Million
€-1.74 Million
≈ $-2.04 Million
-0.063x -150.16%
2005-12-31 €13.39 Million
≈ $15.65 Million
€1.68 Million
≈ $1.96 Million
0.125x -54.99%
2004-12-31 €14.00 Million
≈ $16.37 Million
€3.89 Million
≈ $4.55 Million
0.278x +43.82%
2003-12-31 €9.04 Million
≈ $10.57 Million
€1.75 Million
≈ $2.04 Million
0.193x --

About Genfit S.A.

PA:GNFT France Biotechnology
Market Cap
$473.01 Million
€404.59 Million EUR
Market Cap Rank
#13684 Global
#201 in France
Share Price
€8.08
Change (1 day)
+2.67%
52-Week Range
€3.05 - €9.36
All Time High
€42.98
About

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more